All In Biotech

Drug Trial Radar · NCT07354724

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

May 12, 2026

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Denali Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across various dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).

Conditions

  • Late-onset Pompe Disease

Interventions

  • DNL952Drug

    Intravenous repeating dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)Time frame: 48 weeks
  2. Incidence and severity of infusion-related reacations (IRRs)Time frame: 48 weeks

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California-Irvine

    Irvine, California · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Duke University School of Medicine - Early Phase Research Unit

    Durham, North Carolina · Recruiting

  • The Lysosomal & Rare Disorders Research & Treatment Center

    Fairfax, Virginia · Recruiting

  • SphinCS GmbH

    Höchheim, Germany · Recruiting

  • Erasmus Medical Center

    Rotterdam, Netherlands · Recruiting

  • Royal Free Hospital NHS Trust

    London, United Kingdom · Recruiting

  • Salford Care Organisation Northern Care Alliance NHS Group

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.